Fortress Biotech, Inc.

NASDAQ:FBIO

Biotechnology

Healthcare
$1.89 -1.79%

-$0.06 today

Market cap
$63.03M
Beta
1.23
P/E (TTM)
0.7
EPS (TTM)
$4.05
52W Low $1.70High $4.53

Volume 0.41M

Average 0.43M

FBIO Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Fortress Biotech, Inc.NASDAQ: FBIO

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$7.74M, compared with -$22.32M a year earlier. Trailing-twelve-month operating income was -$55.81M.

Context

  • Operating income amounted to 111.0% of revenue in FY2025, down 80.4 pp from a year earlier.
  • Operating income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether next quarter's operating income reaches the consensus estimate of -$5.27M, a +85.5% change from the same quarter last year.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.74M-61.6% QoQ
Last fiscal yearDec 2025
-$70.22M+36.4% YoY
LTMMar 2026
-$55.81M+43.9% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+65.3%+85.5%+20.2 pp
1 year+36.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(70.22M) USD
Year-over-year change
+36.4%

Operating Income vs competitors

How FBIO compares with its peers on the latest reported figures

  • FBIO's LTM Mar 2026 operating income of -$55.81M is the 6th highest of the 10 companies compared; the peer median is -$48.41M.
  • Its year-over-year change of +43.9% is the 2nd highest of 9, against a peer median of +4.5%.
  • Operating income amounts to 84.4% of revenue for FBIO, versus a peer median of 930.7%.
FBIO Competitors Peer median
Operating Income for FBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$38.18M +166.8%—14.9%
NTRBNutriband Inc.LTM Apr 2026-$8.16M -31.3%—452.6%
GANXGain Therapeutics, Inc.LTM Mar 2026-$19.69M +3.2%——
ADAGAdagene Inc.LTM Jun 2024-$36.99M ——4534.8%
XBITXBiotech Inc.LTM Mar 2026-$48.41M -7.2%——
FBIOFortress Biotech, Inc.LTM Mar 2026-$55.81M +43.9%—84.4%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026-$60.34M +23.7%——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026-$83.66M +5.8%——
IMUXImmunic, Inc.LTM Mar 2026-$109.64M -8.6%——
TCRXTScan Therapeutics, Inc.LTM Mar 2026-$128.7M +7.9%—1408.7%
Peer median (excluding FBIO) -$48.41M+4.5%—930.7%

Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue68.79M75.74M84.51M57.68M63.26M
Cost of Revenue32.08M30.78M22.89M20.88M20.92M
Gross Profit36.71M44.97M61.62M36.8M42.34M
Gross Margin53.4%59.4%72.9%63.8%66.9%
Research & Development128.87M134.88M106.07M56.88M11.9M
Selling, General & Admin86.84M113.66M90.98M87.73M96.4M
Operating Expenses225.25M248.53M203.96M147.18M112.56M
Depreciation & Amortization6.79M9.35M6M4.46M4.66M
EBITDA(146.17M)(193.69M)(135.72M)(104.49M)(20.17M)
EBITDA Margin-212.5%-255.7%-160.6%-181.2%-31.9%
Operating Income(188.54M)(203.56M)(142.34M)(110.38M)(70.22M)
Operating Margin-274.1%-268.8%-168.4%-191.4%-111.0%
Interest Income649K1.4M3M2.68M2.49M
Interest Expense15.31M13.64M12.52M9.93M8.71M
Other Income / Expenses24.19M(9.9M)(11.29M)(10.16M)36.69M
Income Before Tax(164.35M)(213.46M)(153.63M)(120.54M)(33.54M)
Pre-Tax Margin-238.9%-281.8%-181.8%-209.0%-53.0%
Income Tax Expense473K449K521K312K(620K)
Net Income(64.7M)(86.58M)(60.64M)(46M)6.82M
Net Margin-94.1%-114.3%-71.7%-79.8%10.8%
EPS (Basic)(11.85)(14.55)(8.47)(2.69)(0.07)
EPS (Diluted)(11.85)(14.55)(8.47)(2.69)(0.07)
Weighted Avg Shares5.45M5.93M8.11M20.78M27.9M
Weighted Avg Shares (Diluted)5.45M5.93M8.11M20.78M279.02M

Fortress Biotech, Inc.

NASDAQ:FBIO

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.